Germany rejoices at record pharma R&D investment, but regulations still bite
This article was originally published in SRA
Executive Summary
Germany’s research-based pharmaceutical industry has enjoyed record levels of investment in research and development (R&D) in 2007. “The figures show that the research-based pharmaceutical companies place great faith in Germany as a haven for pharmaceutical research,” said Cornelia Yzer, Director General of the German Association of Research-Based Pharmaceutical Companies (VFA).
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.